(Q83517121)
Statements
A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors (English)
Guido Kroemer
Christopher J Twelves
Christophe Massard
Jean-Charles Soria
D Alan Anthoney
A Proctor
Angela Scaburri
Maria Adele Pacciarini
Bernard Laffranchi
Cinzia Pellizzoni
Jean-Pierre Armand
Rastilav Balheda